A Multicenter, Open-label Phase Ib-II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 1308 (Primary) ; BAT 8008 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Bio-Thera Solutions

Most Recent Events

28 Oct 2024 Planned number of patients changed from 204 to 112.
18 Oct 2024 Planned number of patients changed from 50 to 204.
15 May 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight